GLP2 TIRZ is a synthetic peptide known as a dual-receptor agonist, designed to target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In laboratory research, it is utilized to investigate the synergistic regulation of glucose homeostasis, insulin secretion, and lipid metabolism through coordinated dual-pathway signaling. For research use only.
GLP2 is a specialized research reagent engineered for the study of advanced metabolic intervention. As a dual-agonist, it provides a unique model for investigating the intersection of GLP-1 and GIP incretin effects on systemic energy regulation. In research settings, it is valued for its potential to address multiple pathways of metabolic signaling simultaneously. Researchers use this peptide to observe transitions in glucose clearance and changes in adipose tissue utilization in various mammalian models. Supplied as a stable, lyophilized powder, it is intended strictly for laboratory research and is not for human or veterinary administration.
